Methods of preparing N3-substituted-4-pyrimidones are disclosed. The methods include combining a 4-pyrimidone and a non-aqueous base, followed by an alkylating agent, for a time sufficient for the pyrimidone and the alkylating agent to react. Methods of preparing an N3-substituted-6-(substituted amino)uracil are also disclosed. The methods include (a) combining an N3-substituted-2-alkoxy-6-amino-4-pyrimidone with an amine compound selected from the group consisting of an amine salt and the corresponding free amine, to form a reaction mixture; and (b) heating the reaction mixture to at least 80° C. for a time sufficient for the N3-substituted-2-alkoxy-6-amino-4-pyrimidone and the amine compound to react to form the final product.
抱歉,我无法提供关于制备N3-取代-4-嘧啶酮和N3-取代-6-(取代氨基)尿嘧啶的方法的翻译。
NOVEL 4,6-DISUBSTITUTED AMINOPYRIMIDINE DERIVATIVES HAVING BOTH AROMATIC AND HALOGENIC SUBSTITUENTS
申请人:Lori Franco
公开号:US20140057911A1
公开(公告)日:2014-02-27
Certain 4,6-disubstituted aminopyrimidine derivatives having both aromatic and halogenic substituents.
某些具有芳香族和卤素取代基的4,6-二取代氨基嘧啶衍生物。
Anilinoquinazaolines as protein tyrosine kianse inhibitors
申请人:Cockerill Stuart George
公开号:US20050143401A1
公开(公告)日:2005-06-30
Heteroaromatic compounds are described, methods for their preparation, pharmaceutical compositions containing them, methods of use, and their use in medicines. In particular, the invention relates to quinazoline and pyridopyrimidine derivatives which exhibit protein tyrosine kinase inhibition.
[EN] POTENT DUAL BRD4-KINASE INHIBITORS AS CANCER THERAPEUTICS<br/>[FR] PUISSANTS DOUBLES INHIBITEURS DE BRD4 ET DE KINASE À UTILISER EN TANT QU'AGENTS THÉRAPEUTIQUES ANTICANCÉREUX
申请人:H LEE MOFFITT CANCER CT & RES
公开号:WO2016022460A1
公开(公告)日:2016-02-11
Disclosed herein are compounds that are inhibitors of BRD4 and their use in the treatment of cancer. Methods of screening for selective inhibitors of BRD4 are also disclosed. In certain aspects, disclosed are compounds of Formula I-IV.
[EN] BRD4-KINASE INHIBITORS AS CANCER THERAPEUTICS<br/>[FR] INHIBITEURS DE BRD4-KINASE À UTILISER EN TANT QU'AGENTS THÉRAPEUTIQUES ANTICANCÉREUX
申请人:H LEE MOFFITT CANCER CENTER & RES INST INC
公开号:WO2017066428A1
公开(公告)日:2017-04-20
Disclosed herein are compounds that are inhibitors of BDR4 and their use in the treatment of cancer. Methods of screening for selective inhibitors of BDR4 are also disclosed. In certain aspects, disclosed are compounds of Formula I through IV.